clemizole (EPX-100) / Paragon Biosci, Epygenix Therap  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
clemizole (EPX-100) / Paragon Biosci
2021-003425-30: A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100 (Clemizole HCl) as Adjunctive Therapy in Patients with Dravet Syndrome (ARGUS trial) Ensayo multicéntrico, aleatorizado, doble ciego y controlado con placebo, de 20 semanas de duración, de EPX-100 (clemizol HCl) como tratamiento complementario en pacientes con síndrome de Dravet (ensayo ARGUS)

Not yet recruiting
2
100
Europe
EPX-100 (Clemizole Hydrochloride), EPX-100, Oral solution
Epygenix Therapeutics, Inc., Epygenix Therapeutics, Inc.
Dravet Syndrome Síndrome de Dravet, Dravet Syndrome Síndrome de Dravet, Diseases [C] - Nervous System Diseases [C10]
 
 
NCT05066217: EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in Children With Lennox Gastaut Syndrome

Not yet recruiting
2
24
NA
Clemizole HCl, Drug: EPX-100, Drug: EPX-100-matching placebo, Placebo to match EPX-100, Placebo
Epygenix
Lennox Gastaut Syndrome
02/25
02/25
ARGUS, NCT04462770: EPX-100 (Clemizole Hydrochloride) as Add-on Therapy to Control Convulsive Seizures in Patients With Dravet Syndrome

Recruiting
2
100
Europe, Canada, US, RoW
EPX-100 (Clemizole HCl), Clemizole Hydrochloride, Clemizole HCl, Clemizole, Placebo, Placebo to match EPX-100 solution
Epygenix, Forest Hills Lab, Liberyx Therapeutics
Dravet Syndrome
12/24
12/24

Download Options